Oncobiologics Inc (ONS)

[VortMax]

Generic giants gonna need biosim

Teva

Similarly, the success of the Generic giants may depend on their ability to grow their development capability. They will most likely do this through partnerships with companies with a stronger bio-clinical program, but they can bring resources to put behind the development program and commercial capability to these partnerships. In the process, they may have to adapt their business model to the needs of the biosimilars, as it will differ from that of generics, especially in the use of more medical and access-focused customer-facing roles.